Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

by Zacks Equity Research

AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

    Swarup Gupta headshot

    Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses

    by Swarup Gupta

    Dovish comments from Yellen helped global stocks post gains.

      Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod

      by Zacks Equity Research

      Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug Herceptin (trastuzumab).

        Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

        by Zacks Equity Research

        Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

          Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth

          by Zacks Equity Research

          On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).

            Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

            by Zacks Equity Research

            Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

              Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

              by Zacks Equity Research

              Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

                BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer

                by Zacks Equity Research

                BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.

                  Shire Completes NDA Filing for Hemophilia Drug with FDA

                  by Zacks Equity Research

                  Shire plc (SHPG) recently announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A.

                    Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

                    by Zacks Equity Research

                    Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

                      Array (ARRY) Submits NDA for Melanoma Combination Therapy

                      by Zacks Equity Research

                      Array BioPharma (ARRY) announced that it has submitted two new drug applications (NDAs) to FDA, seeking approval for the combination of binimetinib and encorafenib to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

                        Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up

                        by Zacks Equity Research

                        Celsion Corp. (CLSN) shares rose after the company has announced completion of enrolment in a phase Ib study, evaluating its immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer.

                          Roche (RHHBY) Launches Cobas Test for Bacterial Infections

                          by Zacks Equity Research

                          Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.

                            The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

                            by Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

                              Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA

                              by Zacks Equity Research

                              Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).

                                Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

                                by Zacks Equity Research

                                Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

                                  by Arpita Dutt

                                  Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

                                    Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

                                    by Zacks Equity Research

                                    Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

                                      Merck's CETP Inhibitor Reduces CV Risk in Phase III Study

                                      by Zacks Equity Research

                                      Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.

                                        Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval

                                        by Zacks Equity Research

                                        Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.

                                          Allergan Continues to Focus on Acquisitions and Branded Unit

                                          by Zacks Equity Research

                                          We issued an updated research report on Allergan plc (AGN) on Jun 23.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

                                            by Arpita Dutt

                                            All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

                                              Novartis Announces Positive Results for Cardiovascular Drug

                                              by Zacks Equity Research

                                              Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

                                                Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                                                by Zacks Equity Research

                                                Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                                                  Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study

                                                  by Zacks Equity Research

                                                  Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.